At a glance
What is it—and why does it matter?
Noopept is identified in this study as the dipeptide preparation N-phenylacetyl-L-prolylglycine ethyl ester, also labeled GVS-111. The study evaluated Noopept’s impact on transcriptional readouts (NGF and BDNF mRNA) in rat hippocampus and cerebral cortex, quantified by Northern blot analysis. Rat pharmacokinetic assessment indicates the metabolite cyclo-prolyl-L-glycine (CPG) has significantly different pharmacokinetic parameters compared with the parent compound noopept.
Sources for this introduction: [1] [2] [3]
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
What is it?
A molecule, not a product name.
Identity
Noopept is identified chemically as N-phenylacetyl-prolyl-L-glycine ethyl ester.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In the Zakusov Research Institute of Pharmacology a nootropic agent noopept (N-phenylacetyl-prolyl-L-glycine ethyl ester), was developed and introduced into medical practice”
[Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats]. · Abstract
pubmed:30378564:8a9f83006e92:8a9f83006e92
Identity
Noopept is identified in this study as the dipeptide preparation N-phenylacetyl-L-prolylglycine ethyl ester, also labeled GVS-111.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“We studied the effect of original dipeptide preparation Noopept (N-phenylacetyl-L-prolylglycine ethyl ester, GVS-111) with nootropic and neuroprotective properties”
Noopept stimulates the expression of NGF and BDNF in rat hippocampus. · Abstract
pubmed:19240853:025cd10b1e7f:025cd10b1e7f
How does it work?
Target, response, and disposition.
Mechanism
The study evaluated Noopept’s impact on transcriptional readouts (NGF and BDNF mRNA) in rat hippocampus and cerebral cortex, quantified by Northern blot analysis.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Expression of NGF and BDNF mRNA in the cerebral cortex and hippocampus was studied by Northern blot analysis.”
Noopept stimulates the expression of NGF and BDNF in rat hippocampus. · Abstract
pubmed:19240853:025cd10b1e7f:025cd10b1e7f
Pharmacokinetics
Rat pharmacokinetic work identified cyclo-prolyl-L-glycine (CPG) as a noopept metabolite present in both plasma and brain.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“studies of its pharmacokinetics in ratsrevealed that the noopept metabolite found in the rat plasma and brain, cyclo-prolyl-L-glycine (CPG)”
[Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats]. · Abstract
pubmed:30378564:8a9f83006e92:8a9f83006e92
Pharmacokinetics
Rat pharmacokinetic assessment indicates the metabolite cyclo-prolyl-L-glycine (CPG) has significantly different pharmacokinetic parameters compared with the parent compound noopept.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“cyclo-prolyl-L-glycine (CPG), differed significantly in its pharmacokinetic parameters from noopept”
[Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats]. · Abstract
pubmed:30378564:8a9f83006e92:8a9f83006e92
What has been studied?
What the evidence says.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Additional research & classification gaps
2 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (2)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A between-group comparison is reported: sham-operated subjects showed a more pronounced noopept-associated immunotropic response to Aβ (25—35) prefibrillar aggregates than bulbectomized subjects, alongside overall suppressed immunoreactivity in the bulbectomized group.
Research context only—not evidence of a treatment effect.
- The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model
The positive immunotropic effect of noopept to Aβ (25—35) peptide prefibrillar aggregates was more marked in sham-operated compared to the bulbectomized subjects which were characterized by an overall suppression of immunoreactivity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Chemically, noopept is identified as N-phenylacetyl-L-polyglycine ethyl ester.
Research context only—not evidence of a treatment effect.
- [The original novel nootropic and neuroprotective agent noopept].
Experimental investigations of noopept (N-phenylacetyl-L-polyglycine ethyl ester) showed that the new drug exceeds pyracetam both with respect to the effective dose level (1000 times lower for noopept than for pyracetam) and in the spectrum of mnemotropic activity.
Research status + gaps
What still needs better answers?
- No publishable claim yet for: administration, contraindication, effect, interaction, regulatory, safety
- 26 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (19), assurance_score_below_0.72 (5), current_regulatory_source_required (5), extraction_ambiguity (18), high_risk_requires_regulatory_or_two_independent_sources (6), no_direct_support (17)
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model ↗
doi · published 2007-08-01 · retrieved 2026-09-08T21:52:37Z
- [The original novel nootropic and neuroprotective agent noopept]. ↗
pubmed · published 2002-01-01 · retrieved 2026-09-09T18:03:04Z
- Noopept stimulates the expression of NGF and BDNF in rat hippocampus. ↗
pubmed · published 2008-09-01 · retrieved 2026-09-09T18:03:04Z
- [Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats]. ↗
pubmed · published 2018-09-01 · retrieved 2026-09-09T22:29:35Z
Publication history and provenance
Version 2 · Automated assessment · 2026-09-09T22:29:35Z
c98bea2650eebac32cb0cad75878cd7d0b75783cf3bf37f4caf3a4721c17f981